Berliner Effektengesellschaft AG (FRA:BFV)

Elevation Oncology Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	15.3	9.68	17.97	57.52	58.33
Depreciation & Amortization	1.8	4.94	7.76	1.66	-0.08
Other Amortization	3.54	-	-	-	-
Gain (Loss) on Sale of Assets	-0.02	0.01	0	0	0
Gain (Loss) on Sale of Investments	0.51	-	-	0.61	-
Provision for Credit Losses	-	0.07	0.29	0.41	0.05
Change in Trading Asset Securities	-12.21	158.24	227.69	349.31	-198.65
Change in Other Net Operating Assets	6.41	9.6	-117.76	-43.47	-9.57
Other Operating Activities	52.27	-123.1	-148.8	-244.59	311.26
Operating Cash Flow	67.61	59.43	-12.85	121.45	161.33
Operating Cash Flow Growth	13.77%	-	-	-24.72%	943.54%
Capital Expenditures	-0.07	-2.88	-3.19	-1.16	-0.48
Cash Acquisitions	-0.07	-3.75	-5.99	-6.58	-
Investment in Securities	-	-	-0.25	-0.04	-0.03
Purchase / Sale of Intangibles	-9.64	-5.41	-4.4	-15.25	-1.27
Investing Cash Flow	-9.78	-12.04	-13.82	-23.02	-1.77
Issuance of Common Stock	12.87	15.13	14.94	50.89	16.51
Repurchase of Common Stock	-17.32	-19.54	-15.5	-14.88	-8.97
Common Dividends Paid	-6.55	-13.28	-13.39	-13.42	-8.06
Net Increase (Decrease) in Deposit Accounts	18.78	-1.91	14.28	-12.5	-12.33
Other Financing Activities	-13.55	-20.99	-46.65	-53.35	-14.64
Financing Cash Flow	-5.77	-40.59	-46.33	-43.26	-27.48
Net Cash Flow	52.06	6.8	-72.99	55.17	132.08
Free Cash Flow	67.54	56.55	-16.04	120.3	160.85
Free Cash Flow Growth	19.44%	-	-	-25.21%	962.01%
Free Cash Flow Margin	47.89%	52.41%	-11.04%	47.55%	60.08%
Free Cash Flow Per Share	5.18	4.29	-1.21	8.97	11.92
Cash Interest Paid	2.91	1.19	1.21	2.41	1.73
Cash Income Tax Paid	5.42	-16.51	96.33	73.73	40.59

Updated Aug 16, 2024. Source: S&P Global Market Intelligence. Banks template. Financial Sources.